Author(s):
Diptimayee Jena, Pratishya Bhatta, Kirtimaya Mishra
Email(s):
diptijena72@gmail.com
DOI:
10.52711/2231-5659.2024.00033 
Address:
Diptimayee Jena1*, Pratishya Bhatta2, Kirtimaya Mishra1
1Centurion University of Technology & Management, Bhubaneswar, India.
2IMS and SUM Hospital, Bhubaneshwar, Pin - 751003, Odisha, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 3,
Year - 2024
ABSTRACT:
Rituximab is frequently used to treat a variety of B-cell lymphoma. Rituximab alone can produce significant response rates and long-term remissions in several B cell malignancies, whereas combining rituximab with chemotherapy improves overall survival in others. Rituximab is an important part of the treatment for anti-B cell malignancies, although it does not work for everyone, and resistance to it is prevalent. In order to further develop rituximab, which is already a highly effective treatment, it is critical to understand the pathways by which it elicits anti-tumor responses. Diffuse large B-cell lymphoma (DLBCL) is a kind of lymphoma that affects B cells, which are responsible for antibody production.
Cite this article:
Diptimayee Jena, Pratishya Bhatta, Kirtimaya Mishra. Efficacy, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Rituximab (Test Product, Zydus) vs Rituximab (Reference Product, Roche/Genentech) in Patients with Diffuse Large B Cell Lymphoma (DLBCL). Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(3):203-0. doi: 10.52711/2231-5659.2024.00033
Cite(Electronic):
Diptimayee Jena, Pratishya Bhatta, Kirtimaya Mishra. Efficacy, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Rituximab (Test Product, Zydus) vs Rituximab (Reference Product, Roche/Genentech) in Patients with Diffuse Large B Cell Lymphoma (DLBCL). Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(3):203-0. doi: 10.52711/2231-5659.2024.00033 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2024-14-3-2
REFERENCES:
1. Nirmala V. Begu A. Anuradha. Effectiveness of Video Assisted Teaching Programme on Prevention of Oral Cancer among Tobacco Chewers. Asian J. Nur. Edu. and Research. 2012; 2(2): 83-86.
2. Patidar A. Shivhare SC. Ateneriya U. Choudhary S. A Comprehensive Review on Breast Cancer. Asian J. Nur. Edu. & Research. 2012; 2(1): 28-32.
3. Seela SB, Raju PS, Ezhilarasi R. Role of Nursing in Lymphoedema with Breast Cancer Patients. Asian J. Nur. Edu. and Research. 2015; 5(4): 542-4. doi: 10.5958/2349-2996.2015.00111.1
4. Javeth A, Mathur RG, Babu M. A correlational survey to assess the level of stress, coping strategies, and quality of life of female cancer patients related to chemotherapy induced alopecia in Amala Cancer Hospital, Thrissur, Kerala. Asian J. Nur. Edu. and Research. 2017; 7(1): 1-6. doi: 10.5958/2349-2996.2017.00001.5
5. Chellappan S, Rajkumar R, Jeyapal M. Cancer Pain Management: Teaching Program for Terminally ill Cancer Patients. Asian J. Nur. Edu. and Research. 2017; 7(2): 151-154. doi: 10.5958/2349-2996.2017.00030.1
6. Vijayalakshmi K. Assessment of Depression among Cancer Patients. Asian J. Nursing Education and Research. 2018; 8(1): 11-4. doi: 10.5958/2349-2996.2018.00004.6
7. Antony A, Jose D, Kuriakose JR, Thomas L, John M. Knowledge of Adolescents regarding Cancer Prevention and Factors Contributing to Cancer. Asian J. Nursing Education and Research. 2019; 9(4): 515-8. doi: 10.5958/2349-2996.2019.00109.5
8. Morton LM. Wang SS. Devesa SS. Hartge P. Weisenburger DD. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006; 107(1): 265-76. doi.org/10.1182/blood-2005-06-2508.
9. Saranya KV. Ramapriya G. Bansal R. Manimegalai S. Priya PM. Effectiveness of Structured Teaching Program on Knowledge regarding Chemotherapy and Chemotherapy Administration Protocol among Final Year General Nursing and Midwifery Students at selected schools of Nursing Sciences Bengaluru. Asian Journal of Nursing Education and Research. 2022; 12(4): 445-8. doi: 10.52711/2349-2996.2022.00096
10. Swapnil K. Vijay S. Chandrakant M. Targeted Drug Delivery: A Backbone for Cancer Therapy. Asian J. Pharm. Res. 2013; 3(1): 40-46.
11. Pagar KR. Khandbahale SV. Phadtare DG. The Therapeutic Potential of Resveratrol: A Review of Clinical Trials. Asian J. Pharm. Res. 2019; 9(3): 193-199. doi: 10.5958/2231-5691.2019.00031.5
12. Coiffier B. Lepage E. Briere J. Herbrecht R. Tilly H. Bouabdallah R. Morel P. Neste EVD. Salles G. Gaulard P. Reyes F. Lederlin P. Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large-B-cell lymphoma. N Engl J Med. 2002. 2002; 346(4): 235-42. doi:10.1056/NEJMoa011795.
13. Coiffier B. Thieblemont C. Neste EVD. Lepeu G. Plantire I. Castaigne S. Lefort S. Marit G. Macro M. Sabban C. Bolhadj K. Bordessoule D. Ferme C. Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010; 116(12): 2040-45. doi.org/10.1182/blood-2010-03-276246.
14. Swerdlow SH. Campo E. Harris NL. Jaffe ES. Pileri SA. Stein H. Thiele J. Vardiman JW. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. In Lyon: IARC Press 2008.
15. Oken M. Creech H. Tormey C. Horton J. Davis E. McFadden T. Carbone P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649-56.
16. Tarella C. Zanni M. Nicola MD. Patti C. Calvi R. Pescarollo A. Zoli V. Fornari A. Novero D. Cabras A. Stella M. Comino A. Remotti D. Ponzoni M. Caracciolo D. Ladetto M. Magni M. Devizzi L. Rosato R. Boccadoro M. Bregni M. Carradini P. Gallamini A. Majoline I. Prolonged survival in poor-risk diff use large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia. 2007; 21(8): 1802-11. doi: 10.1038/sjleu.2404781.
17. Vitolo U. Chiappella A. Angelucci E. Rossi G. Liberati AM. Cabras MG, Botto Barbara. Ciccone G. Gaidano G. Falchi L. Freilone R. Novero D. Orsucci L. Pavone V. Pogliani E. Scalabrini DR. Salvi F. Tonso A. Tucci A. Levis A. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diff use large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica. 2009; 94(9): 1250-58.
18. Glass B. Ziepert M. Reiser M. Freund M. Trumper L. Metzner B. Feller A. Loeffler M. Pfreundschuh M. Schmitz N. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diff use large B-cell lymphoma. Ann Oncol. 2010; 21(11): 2255-61. doi: 10.1093/annonc/mdq235.
19. Wilson WH. Dunleavy K. Pittaluga S. Hedge U. Grant N. Steinberg SM. Raffeld M. Gutierrez M. Chabner BA. Staudt L. Jaffe ES. Janik JE. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008; 26(16): 2717-24. doi: 10.1200/JCO. 2007. 13. 1391.
20. Morel P. Gaulard P. Gisselbrecht C. Ferme C. Salle G. Tilly H. Briere J. Copin MC. Lederlin P. Hermine O. Theate I. Haioun C. Mounier N. Autologous stem-cell transplantation as consolidation therapy for diff use large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trial LNH98-B2. Ann Oncol. 2008; 19(3): 560-65. doi: 10.1093/annonc/mdm520.
21. Casasnovas RO. Meignan M. Riedinger AB. Bardet S. Julian A. Thieblemont C. Vera P. Bologna S. Briere J. Jais JP. Haioun C. Coiffier B. Morschhauser F. SUV max reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011; 118(1): 37-43. doi.org/10.1182/blood-2010-12-327767.
22. Abramson. JS. Hellmann M. Barnes JA. Hammerman P. Toomey C. Takvorian T. Muzikansky A. Hochberg E. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010; 116(18): 4283-90. doi: 10.1002/cncr.25278.
23. Dumontet C. Mounier N. Munck JN. Bosly A. Morschauser F. Simon D. Marit G. Casasnovas O. Reman O. Molina T. Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin’s lymphoma: a GELA study. Br J Haematol. 2002; 118(1): 210-17. doi.org/10.1046/j.1365-2141. 2002.03565.x
24. Gilbert LA. Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010; 143(3): 355-66. doi: 10.1016/j.cell.2010.09.043.
25. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010; 47(2): 115-23. doi.org/10.1053/j.seminhematol.2010.01.011.
26. Lenz G. Staudt LM. Aggressive lymphomas. N Engl J Med. 2010; 362(15): 1417-29. doi: 10.1056/nejmra0807082.